Assess whether pediatric studies are necessary or waivable (79bae3)

Situation

Disproportionate reporting signal workbook arrived with a literature paper the 505(b)(2) package leans on getting retracted for CMC change-control owner. That is a Pharma & Life Sciences Clinical and Evidence Strategy decision on pediatric studies are necessary in a safety team sitting on a new disproportionate signal.

Decision

CMC change-control owner in a safety team sitting on a new disproportionate signal must choose Pediatric studies are necessary / Waivable using disproportionate reporting signal workbook after a literature paper the 505(b)(2) package leans on getting retracted.

Hypotheses to test

• The population in disproportionate reporting signal workbook is the one a literature paper the 505(b)(2) package leans on getting retracted named, so Pediatric studies are necessary follows for this Clinical and Evidence Strategy file.
• The population in disproportionate reporting signal workbook is adjacent only to a literature paper the 505(b)(2) package leans on getting retracted; Waivable is the honest Pharma & Life Sciences call.
• A safety team sitting on a new disproportionate signal already contained a literature paper the 505(b)(2) package leans on getting retracted before disproportionate reporting signal workbook arrived; no new Clinical and Evidence Strategy path.
• Provenance on disproportionate reporting signal workbook after a literature paper the 505(b)(2) package leans on getting retracted is broken; do not pick Pediatric studies are necessary or Waivable yet.

Analysis required

• Check whether disproportionate reporting signal workbook supports the labeled claim CMC change-control owner would keep.
• Map FDA-response timing and owner in a safety team sitting on a new disproportionate signal.
• Trace CMC, labeling, or pharmacovigilance facts in disproportionate reporting signal workbook after a literature paper the 505(b)(2) package leans on getting retracted.
• For this Pharma & Life Sciences Clinical and Evidence Strategy file, read disproportionate reporting signal workbook against a literature paper the 505(b)(2) package leans on getting retracted and write the one fact that would move pediatric studies are necessary for CMC change-control owner.

Recommendation

Choose Pediatric studies are necessary / Waivable on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (disproportionate reporting signal workbook after a literature paper the 505(b)(2) package leans on getting retracted). Lead with the Pharma & Life Sciences option disproportionate reporting signal workbook can support after a literature paper the 505(b)(2) package leans on getting retracted, then the two facts that force it, then the Monday action for CMC change-control owner in a safety team sitting on a new disproportionate signal.